[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospitals Coventry and Warwickshire NHS Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":148},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,66,93,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100620102","fibrescope-vs-videolaryngoscope-for-nasotracheal-intubation-100620102",false,"NCT07353255","Fibrescope vs Videolaryngoscope for Nasotracheal Intubation","Flexible Fibrescope Versus Video Laryngoscope for Nasotracheal Intubation - A Randomised Comparison","Inclusion Criteria:\n\nPatients aged 18 and above, presenting for elective surgical procedures and requiring general anaesthesia and nasal intubation will be invited to take part in the study.\n\nExclusion Criteria:\n\n* Patients who do not want to take part or do not give consent\n* Patients unable to give written consent.\n* Patient physical status of ASA 4 and 5,\n* Patients deemed to require awake intubation.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients having surgery under general anaesthesia require insertion of a breathing tube to keep the airway open. The technique of inserting a breathing tube through the nose into the trachea (airway) is known as nasotracheal intubation. This is the ideal airway for surgical procedures performed inside the mouth, such as complex teeth extractions and operations on the jaw.\n\nTraditionally, the breathing tube is initially inserted blindly into the nasal cavity. Then, a video laryngoscope (a camera device) or a direct laryngoscope is used to visualise and guide the passage of tube into the trachea. This approach can be associated with difficulty passing the tube and has a high incidence of nasal trauma and nosebleed.\n\nAlternatively, a flexible fibrescope ( flexible camera device) with pre-loaded tracheal tube is passed through the nostril first under vision, gently advanced through the nasal passage and then to the trachea. Once it is correctly placed in the trachea, the breathing tube is railroaded over it. This procedure allows the clinician to visualise the nasal passage and to choose most patent nostril and hence is likely to reduce risk of nosebleed as compared blind passage of tube through the nose. A videolaryngoscope has a camera on the blade that projects the image onto a monitor screen. As this is a rigid device, it can only be inserted through the oral cavity and allows the advancement of tube into the trachea. Both these techniques are currently used in the clinical practice. However, there are no studies to inform anaesthetists whether there are any differences in the incidence of nosebleed.\n\nThe investigators therefore wish to do a randomised comparison between flexible fibrescope and videolaryngocope to assess if use of the former is associated with any reduced risk or severity of nosebleed.",[26],"No Disease","RECRUITING","2026-06-11",{"date":30,"type":31},"2026-06-15","ACTUAL",{"date":33,"type":31},"2026-02-01",{"date":35,"type":20},"2027-01-31",{"name":37,"class":38},"University Hospitals Coventry and Warwickshire NHS Trust","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100588175","optimised-decrement-evoked-potential-deep-mapping-to-guide-ventricular-tachycardia-vt-ablation-in-patients-with-structural-heart-disease-vt-100588175","NCT06937983","Optimised Decrement Evoked Potential (DeEP) Mapping to Guide Ventricular Tachycardia (VT) Ablation in Patients With Structural Heart Disease VT","Opto-DeEP","Inclusion Criteria:\n\n* ≥18 years old\n* Patients with cardiac implantable electronic devices (CIED) (e.g. pacemakers, cardiac resynchronisation therapy (CRT) devices, implantable cardioverter defibrillator (ICD) devices)\n* Eligible for VT ablation as part of standard care (urgent or elective)\n* Ischaemic heart disease and prior myocardial infarction (MI) (using the international definition of MI: Q waves or imaging evidence of regional myocardial akinesis\u002Fthinning in the absence of a non-ischemic cause with documentation of prior ischaemic injury) OR other structural heart disease (such as: arrhythmogenic cardiomyopathy (ACM), or dilated cardiomyopathy (DCM), or hypertrophic cardiomyopathy (HCM), or sarcoidosis, or myocarditis).\n* Catheter ablation of VT ablation using Abbott intracardiac mapping catheter and Ensite intracardiac mapping system.\n\nExclusion Criteria:\n\n* Lacks capacity to provide informed consent\n* New York Heart Association (NYHA) class IV heart failure\n* Life expectancy of less than 12 months\n* Implanted with a ventricular assist device\n* Presence of mobile intracardiac thrombus\n* Reversible cause of VT\n* Women who are pregnant or nursing\n* Both mechanical aortic and mitral valves\n* Enrolment in a concurrent interventional clinical study that in the judgement of the investigator would increase risk to the patient or deem the patient inappropriate to participate in this study.",{"count":48,"type":20},77,[23],"Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder. Special pacemakers called implantable cardiac defibrillators (ICDs) help treat VT episodes, however they do not prevent the VT episodes from occurring. Catheter ablation for VT is a minimally-invasive and established procedure for preventing VT recurrence. This involves placing wires in the heart to find the diseased areas that are responsible for the VT episodes. The diseased areas are shown on computer-generated maps and are later removed via controlled tissue heating (ablation). A major challenge during the VT ablation procedure is locating the diseased area responsible for the VT episodes. Several methods have been described to locate the diseased heart area, however these methods are not always effective.\n\nIn this study, we aim to improve the identification of the diseased heart areas responsible for the VT episodes using a novel method. Our research group have developed, tested and peer-reviewed this improved method of locating diseased areas by looking for signals called decrementing evoked potentials (DeEPs). Ablation will target DeEPs shown on the computer-generated maps. We will assess if VT can be triggered at the end of the procedure. Patients will be monitored over 12 months to see if ablation of DeEPs leads to a reduction in VT episodes. We aim to recruit 77 patients with established heart disease of any cause, who have suffered VT episodes with ICDs. Suitable patients will be identified and recruited from inpatient and outpatient settings. A quality-of-life questionnaire will be completed by patients before and after the ablation procedure. The procedure will be performed as routine standard of care, in the cardiac catheter laboratory across multiple recruiting cardiac centres in the UK providing well established VT ablation service.\n\nOverall, this study will contribute towards developing refined VT ablation techniques, aiming to improve patient outcomes.",[52],"Structural Heart Disease",[54,55,56,57],"Ventricular Tachycardia","Decrementing Evoked Potential mapping","Optimisation parameters","Clinical Applicability","2026-04-09",{"date":60,"type":31},"2026-04-13",{"date":62,"type":31},"2025-04-11",{"date":64,"type":20},"2027-12-03",{"name":37,"class":38},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100560614","robotic-inflammatory-bowel-disease-development-learning-and-efficacy-study-100560614","NCT06579443","Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study","RIDDLE","Inclusion Criteria:\n\n* Aged 18 years or over\n* Undergoing IBD surgery using MIS (minimally invasive surgery) techniques\n* Histological\u002Fradiological evidence of inflammatory bowel disease\n\nExclusion Criteria:\n\n* Planned open surgical approach\n* Lacks capacity to provide informed consent",{"count":74,"type":20},100,"OBSERVATIONAL","To determine if robotic surgery can be performed for inflammatory bowel disease (IBD) patients, to ascertain the optimal robotic set up for multi-quadrant IBD operations and evaluate clinical outcomes in robotic compared to laparoscopic surgery.",[78,79,80],"Inflammatory Bowel Diseases","Crohn Disease","Ulcerative Colitis",[82,83],"Robotic IBD surgery","Laparoscopic IBD surgery","2025-12-02",{"date":86,"type":31},"2025-12-10",{"date":88,"type":31},"2024-07-12",{"date":90,"type":20},"2026-06",{"name":37,"class":38},6,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":103,"conditions":104,"keywords":109,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":39},"100431557","power-myocardial-fatigue-study-a-biomechanical-assessment-of-contractility-of-human-myocardium-100431557","NCT04899635","POWER Myocardial Fatigue Study: a Biomechanical Assessment of Contractility of Human Myocardium","Profiling Biomechanical Responses and Workload of the Human Myocardium to Explore the Concept of Myocardial Fatigue and Reversibility","POWER","Inclusion Criteria:\n\n* All adult patients between 18 to 85-years old undergoing open-heart surgery who can undergo the consent process for the study\n* Healthy donor hearts that are deemed non-transplantable and consent received from a legal representative\n\nExclusion Criteria:\n\nThis criterion is kept to a minimum since the availability of human myocardial samples is finite and dependent on the limited number of patients undergoing cardiac surgery annually within the local hospital.\n\n* Patients who do not have the mental capacity to undergo the consent process\n* For the safety of researchers, patients with evidence of ongoing blood-borne infections such as HIV, or a recent positive test for COVID-19 (within 10 days of last PCR test).","85 Years",{"count":74,"type":20},"To gain a comprehensive understanding of the biomechanical behaviour of human heart to explore the concept of myocardial fatigue in response to a temporal range of preload, afterload and drug-induced inotropy using in-vitro contractile assays.",[105,106,107,108],"Heart Failure","Fatigue; Muscle, Heart","Myocardial Dysfunction","Exhaustion; Heart",[110,111,112,113,114,115],"Myocardial Fatigue","Preload","Afterload","Cardiac Work-loop","Cardiomyocytes","Biomechanical model","2024-06-17",{"date":118,"type":31},"2024-06-18",{"date":120,"type":31},"2021-08-03",{"date":122,"type":20},"2025-04-30",{"name":37,"class":38},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":131,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100474687","ai-models-for-non-invasive-glycaemic-event-detection-using-ecg-in-type-1-diabetics-100474687","NCT05461144","AI Models for Non-invasive Glycaemic Event Detection Using ECG in Type 1 Diabetics","Development and Validation of Artificial Intelligence Models for Non-invasive Glycaemic Event Detection Using ECG in Type 1 Diabetics","Inclusion Criteria:\n\nThe study will be open to all individuals living independently, over 18 years without acute illness or ongoing clinical investigation, or volunteers with a stable medical condition may be included. Volunteers with an ongoing medical condition will only be included after detailed consultation with our clinical and dietetics members of the team; however, it is imperative that volunteers are able to provide written informed consent.\n\nExclusion Criteria:\n\nWhilst the study employs a deliberately open inclusion criterion, the following exclusion measures will be employed:\n\n* Children (under 18 yrs)\n* Any adult who lacks decisional capacity\n* Claustrophobia, isolophobia, recent abnormal exercise, radiation exposure within the preceding 24 hours of entering the whole-body calorimeter and feeling unwell in any way.\n* Needle phobia\n* Any medical\u002Fendocrine problem that could affect energy expenditure (e.g. thyroid problems, Cushing's syndrome)\n* Chronic inflammatory disorders like rheumatoid arthritis, or long term use of steroids or other immunomodulators like cyclosporine, azathioprine.\n* Beta blockers\n* Currently actively losing weight\n* Depression or any psychiatric illness",true,{"count":133,"type":20},30,"This observational study aims to recruit up to thirty T1DM patients from a diabetic outpatient clinic at the University Hospital Coventry and Warwickshire for a two-phase study. The first phase involves attending an inpatient protocol for up to thirty-six hours in a calorimetry room at the Human Metabolism Research Unit under controlled conditions, followed by a phase of free-living, for up to three days, in which participants will go about their normal daily activities without restriction. Throughout the study, the participants will wear commercially available wearable sensors to measure and record physiological signals (e.g., electrocardiogram and continuous glucose monitor). Data collected will be used to develop and validate an AI model using state-of-the-art deep-learning methods for the purpose of non-invasive glycaemic event detection.",[136],"Metabolic Disease",[138],"Endochrine","NOT_YET_RECRUITING","2022-07-12",{"date":142,"type":31},"2022-07-15",{"date":144,"type":20},"2022-09-30",{"date":146,"type":20},"2027-05-01",{"name":37,"class":38},""]